tetano
Editor, Senior Moderator
Microb Cell Fact. 2020 Mar 2;19(1):53. doi: 10.1186/s12934-020-01316-1. [h=1]Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice.[/h]
Lei H[SUP]1[/SUP], Xie B[SUP]2[/SUP], Gao T[SUP]2[/SUP], Cen Q[SUP]2[/SUP], Ren Y[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently.
[h=4]RESULTS:[/h] An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/Anhui/1/2013 (AH-H7N9) virus challenge.
[h=4]CONCLUSIONS:[/h] Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic.
[h=4]KEYWORDS:[/h] Influenza A pandemic; S.cerevisiae EBY100/pYD5-HA; Yeast display technology
PMID: 32122351 DOI: 10.1186/s12934-020-01316-1
Free full text
Lei H[SUP]1[/SUP], Xie B[SUP]2[/SUP], Gao T[SUP]2[/SUP], Cen Q[SUP]2[/SUP], Ren Y[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently.
[h=4]RESULTS:[/h] An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/Anhui/1/2013 (AH-H7N9) virus challenge.
[h=4]CONCLUSIONS:[/h] Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic.
[h=4]KEYWORDS:[/h] Influenza A pandemic; S.cerevisiae EBY100/pYD5-HA; Yeast display technology
PMID: 32122351 DOI: 10.1186/s12934-020-01316-1
Free full text